Research programme: anticancer antibodies - Arana Therapeutics/NIH

Drug Profile

Research programme: anticancer antibodies - Arana Therapeutics/NIH

Alternative Names: ART160; EGX-160

Latest Information Update: 09 Mar 2011

Price : $50

At a glance

  • Originator EvoGenix; National Institutes of Health (USA)
  • Developer Arana Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
  • 16 Mar 2009 Research is ongoing in USA
  • 07 Nov 2006 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top